Tourmaline Bio, Inc. (TRML)
(Real Time Quote from BATS)
$26.97 USD
+0.67 (2.55%)
Updated Nov 4, 2024 03:26 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Tourmaline Bio, Inc. (TRML) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$58.33 | $74.00 | $48.00 | 121.79% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Tourmaline Bio, Inc. comes to $58.33. The forecasts range from a low of $48.00 to a high of $74.00. The average price target represents an increase of 121.79% from the last closing price of $26.30.
Analyst Price Targets (6 )
Broker Rating
Tourmaline Bio, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, seven are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/15/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Not Available | Strong Buy |
10/11/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
9/4/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
8/12/2024 | H.C. Wainwright & Co. | Yi Chen | Strong Buy | Strong Buy |
8/8/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 7 |
Average Target Price | $58.33 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 79 of 252 |
Current Quarter EPS Est: | -0.84 |
TRML FAQs
Tourmaline Bio, Inc. (TRML) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Tourmaline Bio, Inc. (TRML) is $58.33. The current on short-term price targets is based on 6 reports.
The forecasts for Tourmaline Bio, Inc. (TRML) range from a low of $48 to a high of $74. The average price target represents a increase of $121.79 from the last closing price of $26.30.
The current UPSIDE for Tourmaline Bio, Inc. (TRML) is 121.79%
Based on short-term price targets offered by six analysts, the average price target for Tourmaline Bio, Inc. comes to $58.33. The forecasts range from a low of $48.00 to a high of $74.00. The average price target represents an increase of 121.79% from the last closing price of $26.30.